logo

For the Inventor, By the Inventor

New York, NY, United States of America

Ludwig Institute for Cancer Research Limited


USPTO Granted Patents = 528

% Expired Patents = 22.9



Trademarks = 4

Forward Citations = 4,318

Loading Chart...
Loading Chart...

620 inventors (with patents filed for the assignee):

goldMedal Thierry R Boon-Falleur (131 out of 143 patents)

silverMedal Pierre Van Der Bruggen (66 out of 73 patents)

bronzeMedal Lloyd J Old (56 out of 122 patents)

4.  Gerd J Ritter (51 out of 58 patents)

5.  Pierre G Coulie (46 out of 53 patents)

6.  Benoit Van Den Eynde (30 out of 30 patents)

7.  Michael Pfreundschuh (29 out of 31 patents)

8.  Carl-Henrik Heldin (28 out of 40 patents)

9.  Yao-tseng Chen (28 out of 42 patents)

10.  Taha Merghoub (26 out of 44 patents)

11.  David Schaer (26 out of 27 patents)

12.  Ulf Eriksson (26 out of 43 patents)

13.  Marc A Van Dijk (26 out of 42 patents)

14.  Michael Derek Waterfield (26 out of 31 patents)

15.  Jacques Van Snick (25 out of 25 patents)


Core Competencies:
Anti-CTLA-4 Antibodies
TGF-β Antibodies
Nucleic Acid Sequencing
Cancer Treatment
Viral Vectors
Immune Modulators
Tumor Antigens
Haplotype Reconstruction
Monoclonal Antibodies
Protein Multimers
Diagnostic Methods
RNA Sequencing

528 patents:

1. 12734150 - Compositions and methods for increasing T cell function (2026-09-15),
2. 12601006 - TARGETED, LONG-READ NUCLEIC ACID SEQUENCING FOR THE DETERMINATION OF CYTOSINE MODIFICATIONS (2026-04-14),
3. 12473346 - A2/NY-ESO-1 SPECIFIC T CELL RECEPTORS AND USES THEREOF (2025-11-18),
4. 12410467 - Bisulfite-free, whole genome methylation analysis (2025-09-09),
5. 12297276 - Anti-TEM1 antibodies and antigen-binding portions thereof (2025-05-13),
6. 12246066 - Anti-CTLA-4 antibodies and methods of use thereof (2025-03-11),
7. 12221477 - TGF-β3 specific antibodies and methods and uses thereof (2025-02-11),
8. 12195556 - Reversible protein multimers, methods for their production and use (2025-01-14),
9. 12180501 - Viral vectors encoding cancer/testis antigens for use in a method of prevention or treatment of cancer (2024-12-31),
10. 12173370 - Whole-genome haplotype reconstruction (2024-12-24),
11. 12071660 - Bisulfite-free, base-resolution identification of cytosine modifications (2024-08-27),
12. 11993653 - Antibodies and methods of use thereof (2024-05-28),
13. 11987843 - Bisulfite-free, base-resolution identification of cytosine modifications (2024-05-21),
14. 11959136 - Bisulfite-free, base-resolution identification of cytosine modifications (2024-04-16),
15. 11957751 - TGF-β1 specific antibodies and methods and uses thereof (2024-04-16),
Ludwig Institute for Cancer Research (LICR) is a nonprofit organization dedicated to advancing the understanding and treatment of cancer. With a global network of researchers and laboratories, LICR conducts cutting-edge research focused on improving patient outcomes and developing innovative cancer therapies. Through collaboration and scientific excellence, LICR strives to make significant contributions to the field of cancer research and ultimately help patients worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Ludwig Institute for Cancer Research Limited
528 Patents

#36 in New York, NY

#63 in New York

#929 in US

#1,838 in the World

New York, NY (US)
New York, NY, United States of America

Ludwig Institute for Cancer Research Limited

Forward Citations = 4,318

620 inventors:

goldMedal Thierry R Boon-Falleur (131 out of 143 patents)

silverMedal Pierre Van Der Bruggen (66 out of 73 patents)

bronzeMedal Lloyd J Old (56 out of 122 patents)

4.  Gerd J Ritter (51 out of 58 patents)

5.  Pierre G Coulie (46 out of 53 patents)

Please report any incorrect information to [email protected]
Loading…